Search results
Results From The WOW.Com Content Network
Voglibose. Voglibose ( INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. [1] Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company.
Eisai (company) Eisai Co., Ltd. ( Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.
Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman.
Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb ( BMS ), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, [2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Dengue vaccine. Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.
Allergan, plc. 160. 206. In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation). However, this deal was cancelled in April 2016 due to new US tax inversion rules. [12] [13] Had this transaction been completed, this would have been the largest within this industry. 2. 2014. Pfizer.
He is the author/co-author of over 90 research articles/papers in the field of biomedical field. His career spans more than 29 years in research, 16 years of which is in pharmaceutical industrial R&D setting. Dr Kamboj is currently a member of the working group on New TB Drugs Team, India.